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Abstract 
Recent genome-wide association studies have reported that, amongst other 
microglial genes, variants in TREM2 can profoundly increase the incidence of 
developing Alzheimer’s disease (AD). We have investigated the role of 
TREM2 in primary microglial cultures from wild-type mice by using siRNA to 
decrease Trem2 expression, and in parallel from knock-in mice heterozygous 
or homozygous for the Trem2 R47H AD risk variant (from the Jackson 
laboratories). The prevailing phenotype of Trem2 R47H knock-in mice was 
decreased expression levels of Trem2 in microglia, which resulted in 
decreased density of microglia in the hippocampus. Overall, primary microglia 
with reduced Trem2 expression, either by siRNA or from the R47H knock-in 
mice, displayed a similar phenotype. Comparison of the effects of decreased 
Trem2 expression under conditions of LPS pro-inflammatory or IL4 anti-
inflammatory stimulation revealed the importance of Trem2 in driving a 
number of the genes up-regulated in the anti-inflammatory phenotype, 
whether treated with RNAi or performed with microglia carrying the R47H 
variant. In particular, Trem2 knockdown decreased levels of the transcription 
factor STAT6. STAT6 is the key mediator downstream from IL4 and controls 
expression of genes including Arg1, which also showed decreased IL4-
induced expression when Trem2 expression was decreased. LPS-induced 
pro-inflammatory stimulation suppressed Trem2 expression, thus preventing 
TREM2’s anti-inflammatory drive. The importance of Trem2 activity in 
regulating the pro- and anti-inflammatory balance of microglia, particularly 
mediating effects of the IL4-regulated anti-inflammatory pathway, has 
important implications for fighting neurodegenerative disease. 
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TREM2 coordinates anti-inflammatory processes in primary microglia, in part 
by promoting IL4-STAT6 signaling. LPS-induced pro-inflammatory stimulation 
suppresses Trem2. Trem2 R47H knock-in mice showed a decrease of 
microglial density in hippocampus. 
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1. Introduction 
 
Genome-wide association studies (GWAS) continue to reveal variants in 
immune/microglia-related genes that significantly increase the risk of 
developing Alzheimer’s disease (AD). These genes now include TREM2, 
CD33, ABI3 and PLCG2 (Griciuc et al. 2013; Guerreiro et al. 2013b; 
Hollingworth et al. 2011; Jonsson et al. 2013; Malik et al. 2013; Naj et al. 
2011; Sims et al. 2017). These studies particularly emphasize an important 
role of microglia in AD pathogenesis. However, the question of how microglial 
activation contributes to AD development is still far from resolved. Nor is it 
clear how to use these findings to leverage microglial pathways for drug 
discovery. 
 
Triggering receptor expressed on myeloid cells 2 (TREM2) is a 
transmembrane protein containing a single immunoglobulin-superfamily (Ig-
SF) domain. TREM2 expression was first observed in macrophages and 
dendritic cells, but not granulocytes or monocytes (Bouchon et al. 2000; 
Bouchon et al. 2001; Daws et al. 2001). It has since been reported to be 
widely expressed in various cell types derived from the myeloid lineage, such 
as bone osteoclasts (Humphrey et al. 2006; Paloneva et al. 2003), and lung 
and peritoneal macrophages (Turnbull et al. 2006). In the brain, TREM2 is 
predominantly expressed by microglia (Paloneva et al. 2002; Schmid et al. 
2002; Takahashi et al. 2005; Wang et al. 2016). In 2013, two independent 
GWAS studies (Guerreiro et al. 2013b; Jonsson et al. 2013) highlighted a rare 
variant rs75932628-T in exon 2 of the TREM2 gene, causing an arginine-to-
histidine substitution at amino acid position 47 (R47H), to be highly 
significantly associated with increased AD risk. The risk from this variant has 
a comparable effect size to the APOEε4 allele (around 3-fold increased AD 
risk; Benitez et al. 2013; Jin et al. 2014; Jonsson et al. 2013; Murray et al. 
2018; Ruiz et al. 2014). Furthermore, the R47H variant was investigated in 
other neurodegenerative diseases and was also found to be associated with 
frontotemporal dementia, Parkinson’s disease, and amyotrophic lateral 
sclerosis (Cady et al. 2014; Rayaprolu et al. 2013), suggesting a more 
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widespread role for TREM2-related microglial functions in maintaining 
neuronal function/survival throughout the brain. In addition to the R47H 
variant, further TREM2 variants have been revealed to be risk factors of AD or 
other CNS diseases, such as R62H (Jin et al. 2014; Sims et al. 2017), H157Y 
(Jiang et al. 2016), Q33X, T66M and Y38C (Guerreiro et al. 2013a; Guerreiro 
et al. 2013c). All of the TREM2 genetic linkage studies with 
neurodegenerative diseases suggest an important contribution of TREM2 to 
regulating microglial functions with respect to neuronal function/survival in the 
process of disease progression.  
 
Evidence from in vitro studies has accumulated to support the role of TREM2 
in restricting inflammation and promoting phagocytosis. It was first reported in 
a study using primary microglia transduced with flag epitope tagged TREM2 
that TREM2 stimulated microglial chemotaxis, and phagocytosis of 
fluorescent beads (Takahashi et al. 2005). They also showed that Trem2 
knockdown via a lentiviral strategy increased pro-inflammatory gene 
expression and decreased phagocytosis of labeled apoptotic neuronal 
membranes in primary microglia stressed with co-culture of apoptosis-induced 
primary neurons. TREM2 was also found to inhibit LPS-induced pro-
inflammatory markers up-regulated in primary alveolar macrophages in vitro 
(Gao et al. 2013), and the BV-2 microglial cell line (Zhong et al. 2015). With 
particular respect to AD, phagocytosis of Aβ was found to be impaired due to 
lack of or reduced mature TREM2 cell surface expression in studies with 
primary microglia from Trem2 knock-out mice and mutant Trem2 microglial 
cell lines (Kleinberger et al. 2014; Xiang et al. 2016). Recently, it was further 
shown that apolipoproteins and Aβ itself acted as ligands of TREM2 to 
facilitate microglial phagocytosis and clearance of Aβ and apoptotic neurons 
(Atagi et al. 2015; Yeh et al. 2016; Zhao et al. 2018). In general, these studies 
suggest that Trem2 deficiency exacerbates microglial pro-inflammatory 
activation in response to various stimuli, and accompanies impaired 
phagocytosis. However, other cellular functions of TREM2, particularly anti-
inflammatory or alternative activation, and the molecular mechanisms 
mediating the actions of TREM2 are not well understood. 
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In this study, we developed a strategy to investigate the role of microglial-
expressed genes that alter risk for AD in microglia using primary cultures and 
acute knockdown of gene expression using RNAi, and also verifying our 
findings in mouse brain. We used this strategy to explore the effects of acute 
Trem2 deficiency on primary microglia at the transcriptional and functional 
levels, especially when polarized towards a pro-inflammatory or anti-
inflammatory phenotype. We aimed to compare the effect of acute siRNA-
induced knockdown of Trem2 expression to loss-of-function due to the R47H 
mutation by comparing both cultures of isolated microglia and brain tissue 
from wild-type (WT) or recently developed mice carrying the Trem2 R47H 
point mutation from the Jackson laboratories (Trem2 R47H knock-in mice, KI 
mice). The primary effect reported in the R47H mice was a similar reduction of 
Trem2 expression, and this effect was also observed in independent Trem2 
R47H KI mice (Cheng-Hathaway et al. 2018; Xiang et al. 2018). The changes 
in Trem2-mediated effects in this mouse seem to be largely due to this 
decrease of Trem2 expression rather than due to the mutation and so this 
effectively provides us with an in vivo ‘knockdown’ model without the need for 
further intervention, providing a control without transfection, and the possibility 
of verifying effects ex vivo. We find both in vitro and in vivo that decreased 
levels of Trem2 have effects on microglial function and gene expression. We 
investigate the pro- versus anti-inflammatory effects of Trem2 and investigate 
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2. Materials and Methods 	  
2.1. Mice 
 
All experiments were performed in agreement with the Animals (Scientific 
Procedures) Act 1986, with local ethical approval. Trem2 R47H knock-in 
(R47H KI) mice were obtained from the Jackson Laboratory (C57BL/6J-
Trem2em1Adiuj/J; stock number: 027918, RRID: IMSR_JAX:027918; Xiang et al. 
2018), and maintained on a C57BL/6J background. All mice were bred and 
maintained at UCL on a 12 hr light/12 hr dark cycle with ad libitum supply of 
food and water. Genomic DNA was extracted for genotyping using the 
‘HotSHOT’ lysis method. Alkaline lysis reagent (25 mM NaOH, 0.2 mM EDTA 
[pH 12]) was added to tissue samples prior to heating to 95°C for 30 min. The 
sample was then cooled to 4°C before the addition of neutralization buffer (40 
mM Tris-HCl [pH 5]). Mice were genotyped using a quantitative PCR reaction 
utilizing the following primers and probes (Thermo Fisher Scientific):  
 
Forward primer 5’ ACT TAT GAC GCC TTG AAG CA 3’,  
Reverse primer 5’	  CTT CTT CAG GAA GGC CAG CA 3’,  
wild-type probe 5’ VIC- AGA CGC AAG GCC TGG TG -MGBNFQ 3’,  
mutant probe 5’ 6-FAM-	  AGA CAC AAA GCA TGG TGT CG -MGBNFQ 3’  
 
TaqMan genotyping master mix was used according to the manufacturer’s 
instructions.  	  
2.2. Primary microglial culture 
 
Primary microglial cultures were generated from cerebral cortices and 
hippocampi of 1-3-day-old newborns from WT C57BL/6J or Trem2 R47H KI 
mouse strains, following an adapted protocol of Schildge et al. (2013) and 
Saura et al. (2003). For each independent preparation of WT primary 
microglial culture, brains of 4-6 pups from one litter of neonatal mice were 
dissected and pooled. For the Trem2 KI mice, primary cultures from 2-4 pups 
from the same litter were prepared simultaneously but cultured separately, 
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and genotyping was performed after culture preparation. On average, around 
3,000,000~4,000,000 mixed glial cells from the combined cortex and 
hippocampus per pup were obtained. Specifically, after decapitation, the brain 
was quickly extracted and transferred to ice-cold HBSS. The cortices and 
hippocampi from each brain were then isolated by removing all other brain 
regions, meninges and blood vessels. Following mechanical and enzymatic 
(HBSS with 0.25% trypsin) dissociation, cells were centrifuged, collected and 
seeded at a density of 120,000 cells/cm2 in poly-D-lysine coated flasks/wells 
with a glial culture medium (high glucose DMEM with 10% heat-inactivated 
fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin). Cells 
were cultured at 37°C in humidified 5% CO2 and the medium was changed 
every 3 days. After 19-23 days, once the mixed glial cells achieved 
confluence, a mild trypsinization method (incubation with DMEM with 0.05% 
trypsin and 0.2 mM EDTA for 30-45 min) was applied to purify the primary 
microglia by removing the astrocytic cell layer. Conditioned medium from the 
mixed glia was collected before trypsinization. Isolated primary microglial cells 
were collected and seeded in poly-D-lysine coated plates at a density of 
40,000-100,000 cells/cm2 using the collected conditioned medium, except for 
the cultures used for ELISA, which were cultured in fresh medium. Pure 
primary microglia were cultured under the same conditions as the mixed glial 
culture, and experiments were started at 24 hr after isolation.  
 
2.3. Adult mouse brain tissue extraction 
 
Brains were removed from the skull on ice following decapitation, and cut into 
two hemispheres. The hippocampus and cortex were dissected from one 
hemisphere and then snap frozen on dry ice and stored at -80°C until total 
RNA was isolated by homogenisation of tissue with a polytron. The second 
hemisphere was fixed in 4% paraformaldehyde overnight at 4°C and then 
cryoprotected and stored in 30% sucrose in phosphate buffered saline (PBS) 
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2.4. Hippocampal histology 
 
The fixed hemisphere was serially sectioned at 30 µm transverse to the long 
axis of the hippocampus using a frozen microtome (Leica, Germany). For 
assessing microglial density and activity, free floating sections were 
permeabilized in 0.3% Triton-X in PBS three times, blocked (3% goat serum 
in 0.3% Triton X-100 in PBS) for 1 hr at room temperature and incubated with 
primary antibodies at 1:500 dilution in blocking solution (IBA1 rabbit antibody, 
#234003, Synaptic Systems, RRID: AB_10641962; CD68 rat antibody, 
#MCA1957, Bio Rad, RRID: AB_322219), overnight at 4°C. Sections were 
washed, then incubated for 2 hr at room temperature with corresponding 
Alexa-conjugated secondary antibodies diluted to 1:800 in blocking solution 
(goat anti-rabbit Alexa 488 and goat anti-rat Alexa 594 antibodies, Jackson 
ImmunoResearch). Sections were washed, nuclei counterstained with 4’,6-
diamidine-2-phenylindole (DAPI), then mounted with Fluoromount-G medium 
(Southern Biotech). Entire hippocampus was imaged in each section using an 
EVOS FL Auto microscope (Life Technologies) with a x20 objective, by area 
defined serial scanning and a motorised stage. For AIF1 and CD68 staining, 
cells were counted in the CA1: stratum radiatum in subfields of size 91,100 
µm2, stratum lacunosum-moleculare (subfield 68,300 µm2), stratum 
pyramidale and stratum oriens (subfields 76,900 µm2). Microglial cells were 
only counted if their DAPI-stained nucleus could be clearly seen surrounded 
by AIF1 staining with at least two processes protruding from this, and more 
than 50% of the cell body being present in the subfield. CD68 positive cells 
were characterized by the cell body containing greater than 25% 
fluorescence. At least three serial hippocampal sections approximately 720 
µm apart were counted for each mouse. Experimenter was blind to the age 
and genotype of the sample during quantification and analysis. 
 
2.5. BV-2 cell culture 
 
BV-2 cells (maximum passage number < 20), a murine microglial cell line, 
were cultured in medium containing DMEM with 10% heat-inactivated fetal 
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bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 1% mycoplasma removal agent (AbD Serotec), and passaged every 2-4 
days (avoiding confluence of more than 90%). Prior to experiments, BV-2 
cells were collected with Accutase (A6964, Sigma), and seeded on 6-well 
plates at a density of around 10,000 cells/cm2 for testing siRNA sequences.  
 
2.6. siRNA treatment 
 
The following three siRNAs (Ambion) that target mouse Trem2 were tested 
(with a non-targeting siRNA as a control, Ambion, Catalog No. 4457287): 
 
siRNA No. 1 sequences: sense 5’-CCCUCUAGAUGACCAAGAUtt-3’, 
antisense 5’-AUCUUGGUCAUCUAGAGGGtc-3’;  
siRNA No. 2 sequences: sense 5’-GCGUUCUCCUGAGCAAGUUtt-3’, 
antisense 5’-AACUUGCUCAGGAGAACGCag-3’;  
siRNA No. 3 sequences: sense 5’-GCACCUCCAGGAAUCAAGAtt-3’, 
antisense 5’-UCUUGAUUCCUGGAGGUGCtg-3’) 
 
Nuclease-free water was used to make 20 µM siRNA solutions. The 3 Trem2 
siRNAs were tested in BV2 cells and the siRNA No. 2 and No. 3 were 
selected for Trem2 knockdown in primary microglia.  
 
Primary mouse microglia were transfected with either Trem2 siRNA or the 
non-targeting negative control siRNA using the transfection reagent 
Lipofectamine RNAiMax (Invitrogen), following the manufacturer’s 
instructions. The amount of siRNA to volume of Lipofectamine per well was 1 
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2.7. LPS or IL4 treatment 
 
For the microglial activation studies, primary microglia were treated with 1 
µg/ml lipopolysaccharides (LPS; L4391, Sigma) at 3, 6, or 24 hr before 
harvest, or 20 ng/ml Interleukin 4 (IL4; 214-14, PeproTech) at 24 or 48 hr 
before harvest. Time points for the addition of LPS or IL4 treatment are given 
in Figure 1. 
 
2.8. Phagocytosis assay 
 
The phagocytosis assay using the pHrodo green E. coli bioparticles conjugate 
(P35366, Invitrogen) was adapted from the Invitrogen protocol (Garcia-
Reitboeck et al. 2018; Kleinberger et al. 2014). In brief, purified primary 
microglia were cultured on 24-well plates at a density of around 50,000 
cells/cm2 (100,000 cells/well) and transfected with either Trem2 siRNA or the 
negative control siRNA. After 72 hr, microglia were treated with 50 µg pHrodo-
conjugated E. coli per well for 1 hr at 37°C. Cells pre-incubated with 10 µmol 
cytochalasin-D for 30 min prior to the phagocytosis assay were used as a 
negative control. Cells were re-suspended with PBS after the assay, and then 
washed and collected in ice-cold fluorescence-activated cell sorting (FACS) 
buffer (PBS without Ca2+/Mg2+, with 0.5% BSA, 0.05% sodium azide and 2 
mM EDTA). Collected microglia were assessed (10,000 cells counted per 
sample) by flow cytometry (FACSCalibur running CellQuest Pro; Becton 
Dickinson, UK) with excitation at 488 nm and emission at a range of 500-535 
nm. Following identification of single microglial cells with the expected size 
and granularity by forward (FSC-H) versus side (SSC-H) scatter of light, 
microglia with different amounts of phagocytosed fluorescent E. coli and thus 
with different fluorescent intensities were plotted and analyzed using Flowing 
software (developed by Perttu Terho, Turku Centre for Biotechnology, 
Finland; www.flowingsoftware.com).  
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2.9. Primary microglia lysis for gene expression and protein analysis 
 
For gene expression analysis, primary microglia were washed with ice-cold 
PBS three times and then lysed in ice-cold QIAzol RNA lysis reagent 
(Qiagen). Lysed cells were snap frozen on dry ice and stored at -80°C.  
 
To analyze cellular protein, primary microglia were washed with ice-cold PBS 
three times and then lysed in 2X Laemmli dye. Lysed cells were boiled at 
95°C in a heating block for 5 min and stored at -20°C.  
 
For ELISA analyses, supernatants from primary microglial culture were 
collected, centrifuged to remove cell debris and stored at -20°C.  
 
2.10. RNA purification and cDNA preparation 
 
Prior to RNA purification, the primary microglia samples were homogenized 
using a 1 ml syringe and a G21 needle, or hippocampal samples were 
homogenized using a polytron. Total RNA was isolated using miRNAeasy 
columns (Qiagen) following manufacturer’s instructions. The concentration of 
RNA was assessed with a NanoDrop Spectrophotometer (Thermo Scientific), 
with the A260/A280 ratio typically around 2. Randomly selected RNA samples 
from different experiments (Trem2 knockdown and non-targeting siRNA, or 
from Trem2 R47H mice and WT siblings; n = 6 per group), were tested by 
capillary electrophoresis to confirm the quality and concentration of the total 
RNA (Supplementary Figure 1). Typical RNA Integrity values (RIN) of >9.0 
from 10.0 were obtained regardless of siRNA treatment type, or genotype of 
mice. 
 
The same amount of RNA from each sample was first treated using DNase I 
(Amplification Grade, Invitrogen) plus RNaseOUT (Invitrogen). The reverse 
transcription reaction was then performed using the High Capacity cDNA 
Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems) following 
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the manufacturer’s instructions, in parallel with a negative control lacking the 
reverse transcriptase. 
 
2.11. Primer design and test 
 
Primers were designed to span at least two exons and tested for specificity 
against the entire mouse transcriptome using Primer-BLAST (NCBI) and 
supplied by Eurofins MWG Operon. All primers were tested for specificity by 
performing a standard PCR reaction and resolving the products on a 3% 
agarose gel with ethidium bromide, followed by a quantitative RT-PCR 
reaction to obtain the linearity range for primers, calculate primer efficiency 
and test primer specificity using a “melt-curve” analysis. All primer sequences 
are listed in Supplementary Table 1.  	  
2.12. RT-qPCR 
 
The cDNA samples were tested in triplicate with a reverse-transcriptase (RT) 
lacking control in a 96-well plate using the CFX96 system (BioRad), with each 
20 µl reaction containing the cDNA dilution, 0.25 µM of forward and reverse 
primers, and SYBR Green PCR master mix (Bio-Rad). Cycling conditions 
were: 95°C-3 min, 40 cycles of [95°C-10 sec, 58°C-30 sec and 72°C-30 sec], 
and then 72°C-5 min. A melt curve was generated by heating from 60 to 90°C 
with 0.5°C increments and 5 sec dwell time. All RT-qPCR reactions were 
checked for a single peak with the melt-curve analysis reflecting a single PCR 
product. Expression levels of the housekeeping gene Rps28 were shown to 
be stable between the different experimental samples when higher molecular 
weight RNA was measured (Supplementary Figure 1). The raw cycle 
threshold (CT) values of target genes (mean of the triplicates for each 
sample) were normalized to Rps28 CT values for each sample using the delta 
CT method (Matarin et al. 2015). 
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2.13. ELISA of secreted TNF-alpha by primary microglia 
 
The TNF-alpha levels in the primary microglial supernatants were quantified 
using Quantikine® Mouse TNF-alpha ELISA kit (R&D Systems, MTA000B), 
following the manufacturer's instructions. In general, equal volumes of cell 
supernatants, together with the provided buffer, were loaded in duplicate to 
the ELISA microplate and incubated for 2 hr at room temperature. Following 
five washes, wells were then incubated with horseradish peroxidase 
conjugated mouse TNF-alpha antibody for another 2 hr at room temperature. 
The microplate was washed again and incubated with a substrate solution 
prepared with chromogen (tetramethylbenzidine) and hydrogen peroxide for 
30 min before addition of a stop solution with hydrochloric acid. Then the color 
intensity was measured at 450 nm using a plate reader (EL800, BioTek) and 
the TNF-alpha concentrations in microglial supernatants were calculated from 
the standard curve. To account for the differences in the cell number between 
different wells of microglia, cell lysates were collected in parallel with the 
supernatants from the same wells and then tested for levels of a 
housekeeping protein beta-actin (Ab8227, Abcam, RRID: AB_2305186) by 
western blot, which was used for normalization of TNF-alpha levels.   
 
2.14. Western blotting  
 
Cellular protein samples from primary microglia were loaded onto 15% 
polyacrylamide gels and resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis. Proteins were transferred to a 0.45 µm nitrocellulose 
membrane (BioRad) by wet electro-transfer overnight.   
 
Membranes were washed in Tris-buffered saline (TBS; 30 mM NaCl and 30 
mM Tris [pH 7.4]) for 10 min, and then blocked in TBS with 0.1% Tween-20 
(TBST) and 5% non-fat milk for 1 hr at room temperature.  Membranes were 
then probed with primary antibody (STAT6 antibody, 5397S, Cell Signaling 
Technology, RRID: AB_11220421; p-STAT6 (Y641) antibody, 56554S, Cell 
Signaling Technology; AKT (pan) antibody, 4691T, Cell Signaling Technology, 
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RRID: AB_915783; p-AKT (T308) antibody, 2965S, Cell Signaling 
Technology, RRID: AB_2255933; p-AKT (S473) antibody, 4060T, Cell 
Signaling Technology, RRID: AB_2315049; beta-actin antibody, ab8227, 
Abcam, RRID: AB_2305186) diluted in blocking buffer overnight at 4°C. 
Following three washes with TBST, membranes were then incubated with a 
horseradish peroxidase conjugated secondary antibody that was diluted 
1:10,000 in blocking buffer for 1 hr at room temperature. Membranes were 
finally washed 3 more times, and the horseradish peroxidase signals revealed 
with enhanced chemiluminescence detection (ECL, BioRad). Image 




Primary microglia plated on poly-D-lysine coated coverslips were fixed with 
2% PFA for 15 min at room temperature, followed by five washes with PBS. 
Prior to immunocytochemical staining, coverslips were washed in PBS for 10 
min and blocked for 1 hr at room temperature with 8% horse serum diluted in 
PBS with 0.125% Triton-X 100. Coverslips were then incubated overnight at 
4°C with IBA1 antibody (019-19741, Wako, RRID: AB_839504) diluted 
1:1,000 in the blocking solution. After primary antibody incubation, coverslips 
were washed three times with PBS and then incubated for 2 hr at room 
temperature in the anti-rabbit secondary antibody dilution in blocking solution. 
After three washes with PBS and staining with DAPI, coverslips were 
mounted on SuperFrost Plus slides (Fisher) with Fluoromount G (Scientific 
Biotech).  
 
2.16. Imaging and analysis 
 
Coverslips were imaged using an EVOS® FL Auto Cell Imaging System (Life 
Technologies) under a 20X objective. Two coverslips per sample were used 
and three fields of view (480 µm x 360 µm) per coverslip were imaged. AIF1-
positive cells and DAPI were counted with Adobe PhotoShop CS6 software 
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and the microglial purity was calculated as a percentage of the AIF1 cell 




Data are shown as mean ± SEM. The sample size (n) represents the number 
of independent cell preparations or mice. All statistics were performed using 
Prism v7 (Graphpad). For the primary microglial gene expression changes 
with Trem2 knockdown versus the non-targeting siRNA control, single gene 
expression level was normalized as a fold change of the negative control 
within each independent microglial culture preparation, and then a one-
sample Student’s t-test with Bonferroni correction was conducted for statistical 
analysis. For the phagocytosis experiment, a paired Student’s t-test was used 
to compare the Trem2 knockdown group and the non-targeting siRNA control 
group (samples from the same microglial culture preparation were paired). For 
the LPS or IL4 treatment experiments, to assess the impact of Trem2 
knockdown and LPS/IL4 treatment on the gene expression, data were 
normalized to the negative control without LPS/IL4 treatment within each 
individual microglial preparation and then analyzed with two-way ANOVA 
followed by Sidak’s multiple comparison tests when appropriate. The Trem2 
R47H KI expression data in whole hippocampal homogenates were tested by 
one-way ANOVA with Sidak’s multiple comparisons tests when appropriate. 
The Trem2 R47H KI immunohistochemistry data were analyzed using two-
way ANOVA with Sidak’s multiple comparisons tests when appropriate. For 
the primary microglia cultured from the Trem2 R47H KI mice, data were 
analyzed with two-way ANOVA separately for LPS or IL4 treatment using the 
same control samples, then Sidak’s multiple comparisons tests were 
performed when appropriate. Differences were considered significant if 
p<0.05. 
 	    
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/449884doi: bioRxiv preprint first posted online Oct. 22, 2018; 
	   18	  
3. Results 
 
3.1. Establishing an in vitro model of acute Trem2 knockdown  
 
To investigate the functional importance of microglial genes, reported to have 
variants altering risk for AD from GWAS experiments, we established an in 
vitro model where primary microglia were kept in mixed glial culture conditions 
to fully develop for around 21 days before isolation. We used this model to 
elucidate the implications of acute Trem2 knockdown (Figure 1a). The purity 
of our primary microglial culture was validated via immunocytochemistry 
against IBA1 alongside total cell counts from DAPI nuclei staining (97.2±0.3% 
IBA1-positive cells; Figure 1b). Additionally, consistent with previous 
descriptions (Saura et al. 2003), the majority of the microglia showed a typical 
elongated morphology (bipolar or unipolar), with a small proportion of 
ameboid cells. In order to validate the capacity of the microglial culture to be 
polarized in the direction of either the pro- or anti- inflammatory phenotype, 
LPS or IL4 was applied respectively, and expression of typical pro-
inflammatory (Tnf and Il1b) or anti-inflammatory (Arg1 and Tgfb1) genes were 
analyzed via RT-qPCR (Figure 1c). Microglia without LPS expressed low 
transcriptional levels of Tnf and Il1b; while with LPS treatment we observed a 
remarkable increase in the mRNA levels of Tnf and Il1b, presenting as early 
as 3 hr after LPS application, and around 100-fold up-regulation of Tnf and 
1,500-fold of Il1b at 24 hr. In contrast, IL4 treatment induced a significant 
time-dependent up-regulation of Arg1 and Tgfb1 expression (Figure 1c). Arg1 
expression, undetectable in our non-stimulated microglia, reached levels well 
above detection threshold at 24 hr after IL4 treatment, and by 48 hr 
expression levels had further doubled. Tgfb1 expression showed up-
regulation to around 120% of non-stimulated levels at 24 hr and 130% at 48 
hr. These expected changes in Tnf and Il1b, and Arg1 and Tgfb1, serve to 
validate that LPS and IL4 can be used in this system of primary microglia to 
promote a pro-inflammatory and anti-inflammatory fate, respectively. 
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3.2 Acute Trem2 knockdown in primary microglia is effective and 
impairs phagocytosis, validating the preparation 
 
To determine the efficiency of Trem2 knockdown, BV-2 cells were transfected 
with different Trem2 siRNA sequences plus Lipofectamine. Transfected cells 
were collected at 24 and 48 hr and assessed for Trem2 expression levels by 
RT-qPCR (Figure 2a). Three different siRNA sequences against Trem2 were 
tested in parallel to a non-targeting control siRNA. The most effective siRNA 
(sequence 2) gave >80% knockdown of Trem2 mRNA levels compared to the 
non-targeting siRNA control. Thus we chose this sequence for the RNAi 
experiments in primary microglia. The next most effective siRNA against 
Trem2 was sequence 3, giving 50-60% knockdown of Trem2; this second 
siRNA was used to confirm that key findings in the primary microglia were 
dependent on the levels of Trem2 expression (Supplementary Figure 2).  
 
The Trem2 knockdown in the primary microglia performed consistently well 
(Figure 2b), and an average decrease of 79.2±1.1% in the Trem2 mRNA 
levels was obtained. It is, however, interesting to note that basal Trem2 levels 
in the primary microglia were very varied but in all cases Trem2 knockdown 
was effective. 
 
To assess the effect of Trem2 knockdown in this system, we initially tested 
the effects on phagocytosis. Previous studies have already shown impaired 
phagocytosis in primary microglia isolated from Trem2 knockout mice and cell 
lines transfected with FTD-like or AD-associated TREM2 mutations 
(Kleinberger et al. 2014) as well as with Trem2 knockdown in primary 
microglial culture (Takahashi et al. 2005) or in human microglia-like cells from 
induced pluripotent stem cells harboring TREM2 mutations associated with 
Nasu-Hakola dementia (Garcia-Reitboeck et al. 2018). Here we investigated if 
acutely induced Trem2 deficiency via RNAi in the preparation of primary 
microglia used in the present study showed a similar impairment. A 
phagocytosis assay was performed 72 hr after siRNA transfection, to test the 
ability of microglia to phagocytose pHrodo (a pH-sensitive fluorescent dye), 
conjugated to E. coli, followed by quantification of the microglia containing the 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/449884doi: bioRxiv preprint first posted online Oct. 22, 2018; 
	   20	  
fluorescent bacteria in lysosomes by FACS. As a negative control, 
phagocytosis was inhibited with cytochalasin D (a potent inhibitor of actin 
polymerization) before addition of E. coli. We found that microglia with Trem2 
knockdown showed a significant reduction (48.1±9.1%) of phagocytosis 
compared to the non-targeting siRNA treated microglia, confirming previous 
reports and further validating this cell system (Figure 2c).  
 
3.3. Acute Trem2 knockdown causes transcriptional changes in primary 
microglia.  
 
To understand the genetic pathways regulated by TREM2, we next 
investigated the subsequent gene expression changes in microglia caused by 
Trem2-knockdown. We initially tested canonical microglial marker genes 
alongside those we previously found to be potentially implicated in AD in the 
same genetic network as Trem2, following a microarray study of AD-
associated mouse models (Matarin et al. 2015), or genes that have been 
implicated in AD. We initially observed that Trem2 knockdown was 
accompanied by decreased expression of the microglial marker Aif1 
compared to the control-treated group within each culture preparation (Figure 
3). Note that, as these are almost pure microglia cultures, as outlined above, 
the decrease in Aif1 expression relative to the housekeeping gene represents 
a decrease on average per microglial cell rather than a decrease in the 
number of microglia, although this may also occur. This decreased level of 
Aif1 expression relative to the housekeeping gene in Trem2 knockdown 
microglia is consistent with previous evidence that Aif1 is involved in 
phagocytosis (Ohsawa et al. 2000). We then found that Trem2 knockdown 
resulted in a significant down-regulation of a number of microglial genes at 72 
hr after siRNA transfection including C1qa, Cd68, Csf1r, Igf1, Pik3cg, Spi1, 
Tnf and Tgfb1 (Figure 3), suggesting that Trem2 is required to maintain the 
levels of these genes under non-stimulated conditions in vitro. It is interesting 
to note that Csf1 receptor is known as a survival and developmental factor for 
microglia (Elmore et al. 2014; Ginhoux et al. 2010), and so this could be 
associated with a decreased survival of microglia after Trem2 knockdown. 
Interestingly, we saw that the levels of some microglial-specific genes such as 
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Plcg2 and Il1b were not significantly altered when Trem2 expression was 
knocked down, indicating that Trem2 is not required to maintain the 
expression of all microglial gene expression. Overall, acute Trem2 knockdown 
produced a significant change in the gene expression profile of microglia 
under non-stimulated conditions, which might result in a shift of the microglial 
functional phenotype.  
 
3.4. LPS stimulation dramatically suppresses Trem2 gene expression in 
primary microglia. 
 
An important outstanding question is how Trem2 is regulated; our previous 
work in transgenic mouse models associated with AD showed that the 
expression levels of Trem2 were increased up to 6-fold in tight correlation with 
amyloid pathology (Matarin et al. 2015). To begin to investigate how Trem2 
expression is regulated, microglia were stimulated with LPS to induce 
classical pro-inflammatory responses. We first found that, in the control cells, 
LPS treatment strongly down-regulated Trem2 expression (Figure 4a), which 
was consistent with the previous findings in primary mixed glial cell cultures 
and peritoneal macrophage cell cultures (Schmid et al. 2002) and primary 
microglia (Owens et al. 2017). The time course analysis showed that the 
Trem2 expression started to drop to around 90% of the levels measured in 
non-stimulated cells from as early as 3 hr after LPS addition, and then 
continued decreasing and reached levels as low as 10% of non-stimulated 
levels by 24 hr. This suggests that pro-inflammatory conditions inhibit 
microglial Trem2 expression, which might result in a state of temporary or 
chronic ‘TREM2-deficiency’ in microglia.  
 
The expression levels of Tnf and Il1b, two typical pro-inflammatory markers, 
were greatly increased in our LPS-treated microglia from as early as 3 hr after 
LPS application. As expected, considering so little Trem2 remained under 
these conditions, knockdown of Trem2 had little effect on LPS-induced gene 
expression with up-regulation of Tnf or Il1b being unchanged at the 
transcriptional level with Trem2 knockdown compared to control cultures 
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(Figure 4b). It is, however, interesting to note that the up-regulation of Tnf and 
Il1b happened considerably more rapidly than the down-regulation of Trem2, 
with Trem2 knockdown not affecting the dramatic increase in expression of 
these genes at 3 hr when Trem2 was only slightly affected by LPS treatment. 
This may suggest that these pathways are unconnected under these 
conditions. We further investigated whether the protein level of TNF-alpha 
released from the microglia 24 hours after LPS treatment was affected by 
acute Trem2 knockdown. Consistent with the transcriptional results, ELISA 
analysis of the microglial-conditioned medium showed that LPS strongly up-
regulated microglial TNF-alpha production, but there was no significant 
change caused by Trem2 knockdown (Figure 4c).  
 
Considering the time-dependent knockdown of Trem2 by LPS, we were 
interested to investigate the effects of this pro-inflammatory treatment on the 
genes that we had previously tested for effects of Trem2 knockdown under 
non-stimulated conditions (Figure 4d). Genes such as C1qa and Igf1 showed 
a similar pattern of significant time-dependent down-regulation to that of 
Trem2 with LPS stimulation. Expression of Cd68 and Csf1r, which were 
strongly down-regulated by siRNA-induced knockdown of Trem2 showed a 
trend towards also being down-regulated in response to the LPS stimulation. 
In contrast, expression of the Spi1 (PU.1) transcription factor in the microglia 
with LPS showed at least a 3.5-fold increase in levels compared to that in the 
control group, which was observed to start as soon as 3 hr after application, 
and maintained until at least 24 hr. Spi1 expression levels were decreased by 
Trem2 knockdown, regardless of the LPS-treatment. Aif1 expression was also 
increased by LPS stimulation but this only occurred after 24 hours and was 
again independent of Trem2 knockdown. Pik3cg expression also tended to be 
up-regulated with LPS, and again Trem2 knockdown significantly decreased 
Pik3cg expression independent of LPS. Our data with Spi1, Aif1 and Pik3cg 
suggest that these genes were partially regulated by TREM2, as seen when 
Trem2 is knocked down, but can still be induced independently of TREM2 
under the condition of LPS treatment, when there is little remaining Trem2 
expression. Together, these data suggest that a major effect of pro-
inflammatory LPS stimulation in primary microglia is suppression of Trem2 
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expression. In general, the other LPS-dependent effects on gene expression 
studied here were apparently independent of Trem2 expression. However, 
considering the decreased expression of Trem2 under pro-inflammatory 
conditions, it is not surprising that siRNA-induced knockdown of Trem2 had 
little additional effect.  It is possible that Trem2 regulates expression of these 
genes and that these effects were thus dependent on the fact that Trem2 
levels were suppressed by LPS. 
 
3.5. Trem2 is involved in microglial anti-inflammatory responses with IL4 
 
Next we studied the effect of acute Trem2 knockdown on the alternative anti-
inflammatory activation of microglia. IL4 was applied to the cells that had 
previously been treated either with siRNA against Trem2 or the non-targeting 
siRNA, and cells were analyzed at 24 hr and 48 hr after IL4 addition. We first 
found that microglial Trem2 expression upon IL4 treatment was maintained at 
a similar level to that under the basal condition (Figure 5a). As expected, the 
Trem2 knockdown group showed significantly lower levels of Trem2 than the 
control group. We next investigated two anti-inflammatory markers Arg1 and 
Tgfb1 (Figure 5b). The Arg1 gene expression was undetectable under non-
stimulated conditions by RT-qPCR. Upon IL4 treatment, Arg1 expression was 
detectable and showed a time-dependent up-regulation; however, this up-
regulation was considerably decreased in the Trem2-knockdown group (two-
way ANOVA: interaction between main effects of Trem2 knockdown and IL4 
treatment, p=0.05). The Tgfb1 expression also showed an increase with IL4 
stimulation, however, in contrast to Arg1 the effect of Trem2 knockdown and 
IL4 showed no interaction.   
 
We went on to compare the effect of the anti-inflammatory stimulus on the 
gene expression levels of pro-inflammatory markers Tnf and Il1b (Figure 5c). 
In contrast to the effect described above for the inflammatory LPS stimulus, 
the anti-inflammatory IL4 treatment decreased expression of both markers 
(two-way ANOVA: main effect for IL4 treatment, p<0.001 for Tnf, and p<0.01 
for Il1b). In the case of Tnf, the knockdown of Trem2 also decreased 
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expression levels but in an IL4-independent manner. In contrast Trem2 
knockdown had no significant effect on Il1b expression. Collectively, the IL4-
induced microglial response was accompanied by stable Trem2 expression, 
and suppressing Trem2 mRNA levels via RNAi resulted in attenuation of at 
least part of the anti-inflammatory pathways, which led to a pronounced 
inhibition of Arg1 up-regulation.  Together these results suggest that Trem2 
tends to push the microglia towards an anti-inflammatory phenotype while a 
pro-inflammatory stimulus prevents this drive by decreasing Trem2 
expression thus shifting the balance further towards pro-inflammation.       
 
Next, to understand which other genetic pathways are regulated by TREM2 in 
anti-inflammatory conditions, we investigated the expression of the genes 
tested previously, but now in response to IL4 (Figure 6). Expression of C1qa, 
Cd68 and Igf1 were all found to be significantly up-regulated with IL4 
treatment, with tendencies for Csf1r and Spi1 also to increase with IL4, which 
is similar to what we saw in transgenic mice in correlation with plaque load 
(Matarin et al. 2015; www.mouseac.org). Neither Aif1 nor Plcg2 expression 
were changed with IL4. Interestingly, the expression of all of these genes was 
significantly lower in cells with acute Trem2 knockdown, and was not 
dependent on IL4 stimulation (no significant interaction of knockdown versus 
IL4). These data together suggest that the effect of TREM2 on the microglial 
gene expression profile pushes microglia towards an anti-inflammatory 
phenotype. However the lack of interaction between the effects of Trem2 
knockdown and IL4 on expression of most of these genes (except Arg1) 
suggests that the effects on these genes are independent parallel pathways 
which have similar endpoints. Interestingly, the effects of IL4 stimulation on 
gene expression mimic the changes seen in association with plaque 
development in transgenic mice where Trem2 levels are also strongly 
increased, whereas the pro-inflammatory effects of LPS have the opposite 
effect. 
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3.6. TREM2 is involved in maintaining normal STAT6 levels in microglia 
 
As microglial Arg1 up-regulation caused by IL4 stimulation interacted with and 
was largely suppressed by acute Trem2 knockdown, we next investigated 
whether there was an intersection between the IL4 and TREM2 pathways. 
The phosphorylation of the transcription factor STAT6 is a key step 
downstream in the IL4 cascade that leads to Arg1 expression (Gordon and 
Martinez 2010; Luzina et al. 2012; Nelms et al. 1999). We thus performed 
western blotting to test whether total or phosphorylated levels of STAT6 were 
changed in primary microglia with acute Trem2 knockdown with or without IL4 
stimulation (Figure 7a and 7b). We found a slight but significant IL4-induced 
increase in STAT6 levels but, independent of IL4, knockdown of Trem2 
caused a substantial decrease of the STAT6 total protein levels in the 
microglia (two-way ANOVA: main effect of IL4-treatment, p<0.05; main effect 
of Trem2 knockdown, p<0.0001, no interaction). IL4 caused robust 
phosphorylation of STAT6, with phosphorylated STAT6 not detectable in the 
absence of IL4 but clearly measurable 48 hr after IL4 treatment. Trem2 
knockdown also decreased the total levels of phosphorylated STAT6 but this 
could be explained by a decrease in the overall levels of STAT6 rather than 
an effect on phosphorylation per se. The expression level of the Stat6 gene 
was also decreased with Trem2 knockdown (Figure 7c), and so confirms the 
decreased levels of the translated protein. These results suggest that TREM2 
deficiency leads to a smaller STAT6 pool in microglia, resulting in decreased 
amount of phosphorylated STAT6 upon IL4 stimulation. This is consistent with 
the decrease in IL4-induced Arg1 expression caused by reduced STAT6-
dependent microglial gene transcription in response to decreased Trem2 
expression.  
 
TREM2 signaling is also mediated by the PI3K/AKT pathway (Paradowska-
Gorycka and Jurkowska 2013; Zheng et al. 2017), and so we also 
investigated the effects of Trem2 knockdown on the AKT signaling in primary 
microglia (Figure 7d and 7e). Different from the decrease of total STAT6 
protein levels, the total AKT protein level was not significantly affected by 
Trem2 knockdown, although there was a slight increase in AKT levels in 
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response to IL4 treatment. We then tested activation of AKT, and found that 
AKT phosphorylation at both Thr308 and Ser473 relative to total AKT was 
significantly reduced in Trem2 knockdown microglia (two-way ANOVA: main 
effect of Trem2 knockdown, p<0.01 for phosphoT308-AKT and p<0.05 for 
phosphoS473-AKT), and this was independent of IL4 stimulation (no 
interaction between knockdown and IL4). This is not surprising considering 
that PI3K-AKT signaling is downstream of TREM2, but the unchanged total 
AKT level suggests that the STAT6 change is not due to general changes in 
the health and metabolic status of microglia in our cultures. 
 
3.7. Decreased microglial density and down-regulated Trem2 expression 
in the hippocampus of Trem2 R47H knock-in mice 
 
The RNAi strategy allowed us to investigate the general effects of acute 
Trem2 ‘loss-of-function’. As the risk of AD in humans is greatly increased by 
variants in the TREM2 gene, we then aimed to test the effect of the most 
common of these variants, the R47H mutation, and compare its effects to 
those of Trem2 knockdown. We thus employed mice with knock-in of a R47H 
point mutation into the endogenous mouse Trem2 gene (Jackson Laboratory, 
stock # 27918) to study whether the AD-related variant R47H caused similar 
changes in gene expression, and pro- or anti-inflammatory responses to the 
RNAi-mediated ‘loss-of-function’. The primary effect in these Trem2 R47H KI 
mice was a substantial gene dose-related decrease in Trem2 expression in 
hippocampal tissue from the mice (Figure 8a). This has subsequently been 
shown to be due to a splice effect that seems to occur in mice but not in 
humans (Xiang et al. 2018). Reduced expression of Trem2 was also seen in 
an independently generated Trem2 R47H KI model (Cheng-Hathaway et al. 
2018). We can thus consider this R47H mouse line as a good model for 
verifying the effects of Trem2 down-regulation in vivo to compare to our 
findings with RNAi-mediated knockdown of Trem2 presented above. While the 
down-regulation of the gene together with the mutation is less than ideal for 
studying the effect of the R47H mutation, comparison of the two models can 
also give initial information on this subject. 
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In the first instance we investigated the effect of the knockdown in whole 
tissue from the mouse brain. Considering the decrease in Csf1r due to Trem2 
knockdown in the microglial cultures, we hypothesized that microglial 
numbers and survival may be affected in the Trem2 R47H mice. To this end, 
we quantified microglial density in different layers of the hippocampal CA1 
region at 4 months of age, using immunohistochemistry with an antibody 
against IBA1, and found that homozygous Trem2 R47H KI mice displayed a 
significant decrease in the number of microglia compared to WT mice, which 
was consistent in all four CA1 layers (two-way ANOVA: main effect of 
genotype p<0.01; Figure 8b and 8c). Interestingly, we also observed a 
significant decrease of CD68 positive microglia in the homozygous Trem2 
R47H mice (two-way ANOVA: main effect of genotype p<0.0001). This 
change was not primarily due to the total microglia number change because 
the proportion of CD68 positive microglia also showed a substantial decrease 
(two-way ANOVA: main effect of genotype p<0.001; Figure 8b and 8c). CD68 
(macrosialin) is a lysosomal glycoprotein associated with phagocytosis 
(Holness and Simmons 1993; Saito et al. 1991). This result suggests that, in 
addition to slightly reduced microglial density in the hippocampus of 
homozygous Trem2 R47H mice, phagocytosis would also be reduced in the 
surviving microglia. This is consistent with our findings above of reduced 
phagocytosis in cultured microglia following Trem2 knockdown. 
 
We assessed the microglial activation status in the hippocampus of R47H 
Trem2 KI mice at 4 months of age by investigating the expression of a battery 
of microglial genes covering pro- and anti-inflammatory functions, and other 
microglial processes (Figure 8a). Overall, at 4 months of age, a number of 
genes, shown to be dependent on Trem2 expression from our knockdown 
studies above, did not show any significant difference in the hippocampus of 
the Trem2 R47H KI mice compared to WT siblings, such as Aif1, Cd68, Igf1, 
Csf1r and Stat6 relative to the Rps28 housekeeping gene (Figure 8a). It is 
important to note that in the hippocampal tissue, the gene expression in 
microglia is greatly diluted by the much greater contribution of other cell types 
and so small changes in gene expression will be much more difficult to detect 
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than in the primary microglia cultures. However part of the difference is likely 
also to come from the moderating effects of the mixed cell environment and 
the activation state of the microglia under these conditions. In summary, the 
Trem2 R47H KI mice showed that reduced Trem2 expression resulted in 
predominantly a phenotype of a slight but significant decrease in microglial 
numbers and also lower CD68-positive microglia in the CNS environment of 
healthy young adult mice. This may prime the mouse for neurodegeneration 
later in life with aging or other environmental factors.  
 
3.8. Down-regulated Trem2 expression and impaired Arg1 induction in 
primary microglia from Trem2 R47H knock-in mice 
 
Next, to separate the microglia from other cell types and to compare the 
effects on gene expression of acute Trem2 knockdown with siRNA described 
above to decreased expression throughout the life of the mouse, without the 
need for transfection, microglia isolated from the Trem2 R47H mice were 
stimulated towards a pro- versus anti-inflammatory fate as above. Again, the 
primary effect in the microglia from the R47H KI mice was a substantial gene 
dose-related decrease in Trem2 expression, relative to Rps28 (Figure 9a), 
with the microglia isolated from the homozygous Trem2 R47H mice 
expressing very similar levels of Trem2 to the microglia from WT mice after 
knockdown of Trem2, or in the hippocampal tissue from these mice. Also as 
before, we observed a strong down-regulation of microglial Trem2 expression 
in response to LPS treatment, and conversely maintenance of Trem2 
expression with IL4 treatment, which was consistent with our RNAi 
experiments.  
 
We next investigated whether the decreased expression in microglia from the 
R47H KI mice caused changes to gene expression in relation to LPS or IL4 
treatment. With most genes tested the results obtained were compatible with 
the effects of the acute siRNA-induced Trem2 knockdown, described above 
(Figure 9b, 9c and 10). For LPS treatment the one exception was Tnf. In 
contrast to the acute RNAi experiments in which Tnf expression was 
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dramatically increased but with no effect of Trem2 knockdown, significant 
changes were seen between the WT and Trem2 R47H KI mice. After LPS 
treatment, heterozygous microglia carrying one allele of the Trem2 R47H 
showed significantly higher Tnf levels compared to WT and homozygous 
Trem2 R47H-derived microglia. However as the homozygous R47H cells 
showed a tendency for reduced Tnf expression in non-stimulated conditions, 
we calculated the fold-change in Tnf up-regulation in response to LPS and 
found that the up-regulation was significantly increased for the homozygous 
R47H cells (around 200-fold increase) compared to WT (around 150-fold 
increase). The expression levels for Il1b also showed a significant increase in 
response to LPS, as above, but in this case there was no significant effect of 
genotype, and so we saw a similar fold-change in Il1b up-regulation evoked 
by LPS for the WT and R47H variant microglia (around 800-fold increase). 
The difference in the pro-inflammatory gene response to LPS between the 
Trem2 knockdown and R47H-carrying cells suggests that either the R47H 
mutation causes an additional effect to the knockdown or the microglia 
expressing decreased Trem2 levels throughout life in vivo may, once cultured 
outside the brain, be more prone to becoming pro-inflammatory. Either way 
the microglia from the R47H Trem2 KI mice are able to respond to the pro-
inflammatory LPS stimulus similarly to the WT mice or to mice with RNAi-
induced knockdown, but may also show a slightly enhanced pro-inflammatory 
response for some markers. 
 
In terms of genes that are induced by the IL4 anti-inflammatory stimulus, 
results were again generally similar to the effect of RNAi-induced knockdown. 
Arg1 expression was strongly increased by IL4 treatment and the decreased 
Trem2 expression in the microglia from Trem2 R47H KI mice significantly 
prevented this change in a gene dose-dependent manner (Figure 9c, one-way 
ANOVA: main effect of genotype p=0.002, Sidak’s multiple comparisons: 
p=0.08 for WT versus heterozygous, and p=0.01 for WT versus homozygous). 
The other anti-inflammatory marker Tgfb1 was significantly decreased in 
homozygous Trem2 R47H microglia independent of IL4-treatment, and the 
fold-change in Tgfb1 up-regulation in response to treatment was similar for 
WT and homozygous R47H cells. These findings suggest that separate 
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mechanisms regulate basal levels of some genes like Tgfb1 (which may be 
Trem2-dependent at least in part), compared to mechanisms that regulate 
levels following induction (which can be Trem2-independent). Overall, the 
LPS-induced pro-inflammatory response was largely unaffected in the 
microglia carrying Trem2 R47H alleles, but some aspects of the anti-
inflammatory response to IL4 showed strong impairment with decreased 
Trem2 expression, consistent between the Trem2 knockdown and knock-in 
experiments. 
 
Similarly to the Trem2 knockdown experiments, other genes for which 
expression was increased in response to IL4 in, such as Igf1, Cd68 and C1qa, 
showed decreased expression in the homozygous Trem2 R47H microglia, 
regardless of IL4-treatment (Figure 10; two-way ANOVA: main effect of IL4-
treatment, and main effect of Trem2 genotype, but no interaction for Igf1, 
Cd68 and C1qa). As with the RNAi experiments, LPS decreased the 
expression of Igf1, Cd68 and C1qa. As above, all expression data was 
normalized to Rps28. Next we saw that Aif1 expression was also decreased 
in the homozygous R47H microglia relative to both WT and heterozygous 
R47H cells as in our knockdown experiments above (Figure 10). Note the 
heterozygous R47H microglia showed no changes in Aif1 levels despite a 
significant reduction in Trem2 expression suggesting this effect requires a 
certain threshold of knockdown. Expression of Csf1r and Plcg2 were also both 
significantly decreased in the microglia from the Trem2 R47H KI mice. 
However, for these genes the effect of genotype was already apparent in the 
cells from heterozygous R47H KI mice, independent of the presence of IL4 or 
LPS (Figure 10; two-way ANOVA: main effect of treatment, and main effect of 
Trem2 genotype, but no interaction for Csf1r and Plcg2). Similarly to the 
siRNA knockdown experiments and in contrast to Igf1, Cd68 and C1qa, 
expression of Csf1r was not affected by IL4, but was decreased by LPS 
(Figure 10; two-way ANOVA: main effect of LPS-treatment, and main effect of 
Trem2 genotype, no interaction). In the case of Plcg2, the IL4 treatment 
caused a small but significant decrease in Plcg2 expression compared to 
controls which was not evident in the knockdown experiment (two-way 
ANOVA: main effect of IL4-treatment, and main effect of Trem2 genotype, no 
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interaction). Unlike all the other genes tested, Plcg2 expression was 
increased by LPS (two-way ANOVA: main effect of LPS-treatment, and main 
effect of Trem2 genotype, no interaction).  These findings confirm that 
decreased expression of Trem2 in the R47H KI mice, similarly to the siRNA 
knockdown model, tend to make Trem2 less effective in pushing the microglia 
to an anti-inflammatory phenotype compared to wild-type Trem2. While this is 
mostly because of a decrease in expression of Trem2, some additional 
mutation-specific effects may enhance the pro-inflammatory phenotype, with 
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4. Discussion 
4.1. Trem2 R47H knock-in mice can largely be considered a model of in 
vivo Trem2 down-regulation 
 
Of the many genes that have been revealed in GWAS to increase the risk of 
AD, variants of TREM2 have high odds ratios. The most common of these is 
the R47H mutation. We thus aimed to investigate the effect of this mutation in 
Trem2 R47H KI mice. However in the present study we find that the primary 
phenotype of these mice both in primary microglial cultures and in brain tissue 
is a substantial gene-dose-dependent decrease in the expression of Trem2 
compared to WT mice. This effect has recently been described by Cheng-
Hathaway et al. (2018) and Xiang et al. (2018) studying the same mouse line 
used here from the Jackson Laboratory, and an independent Trem2 R47H KI 
mouse line. This does not occur in human tissue with this mutation but 
appears to be a mouse specific effect related to altered splicing. Hence we 
can largely consider these mice as a model of Trem2 down-regulation 
allowing us to validate our siRNA data in primary microglia and investigate the 
effect of Trem2 down-regulation in vivo. Any differences between the siRNA 
and Trem2 R47H KI data may give initial clues to the effect of the mutation 
but this could also be due to the difference between expression throughout life 
in vivo versus acute transfection of the cells with siRNA. By investigating 
microglial density in fixed brains from the Trem2 R47H mice, we saw a 
decrease in the density of microglia in vivo in the hippocampus, and that the 
remaining microglia had dramatically reduced CD68 protein levels. This raises 
the question as to whether any other changes that we found in Trem2 R47H 
microglia are directly due to the mutation itself or downstream of its effect on 
impairing Trem2 expression, and so we studied in parallel the effect of Trem2 
knockdown using siRNA in primary microglia and compared this to the Trem2 
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4.2. siRNA-induced knockdown of Trem2 largely mimics the Trem2 R47H 
phenotype in non-stimulated conditions 
 
Knockdown of Trem2 in the primary microglia transfected with siRNA showed 
similar effects to those seen in microglia from the Trem2 R47H KI mice. In 
both preparations Csf1r expression was decreased. Pharmacological 
blockade of CSF1 receptors has been shown to impair microglial survival and 
can completely remove microglia from the mouse brain (Dagher et al. 2015; 
Elmore et al. 2014; Olmos-Alonso et al. 2016). These findings together with 
the decreased density of microglia in the hippocampus of Trem2 R47H mice, 
makes it likely that the decrease in Csf1r expression in the microglia with 
decreased Trem2 expression contributes to reduced survival of microglia. The 
knockdown of Trem2 decreasing survival or altering the metabolism of 
microglia is consistent with previous studies (Ulland et al. 2017; Wang et al. 
2015; Wu et al. 2015; Zheng et al. 2017). Interestingly no difference in Csf1r 
expression was seen in the remaining microglia in the brain tissue from the 
young adult KI mice, possibly suggesting different populations of microglia 
with loss of those more vulnerable to the effects of Trem2 knockdown than 
others, at least in whole tissue. Differences in gene expression profiles of 
different microglial populations have been recently described using single cell 
RNA-seq (Hammond et al. 2018; Keren-Shaul et al. 2017). 
 
Igf1 expression was also decreased when Trem2 expression was knocked-
down or if the Trem2 R47H variant was carried by the primary microglial 
cultures. Igf1 is abundantly expressed by microglia during postnatal 
development, aging, or following brain injuries and plays a vital role in 
promoting neuronal survival (Fernandez and Torres-Aleman 2012; Kohman et 
al. 2012; Thored et al. 2009; Ueno et al. 2013). While this may not affect 
microglial survival as the IGF1 receptor is found largely on neurons, it could 
contribute to neurodegeneration, being an important factor in neuronal 
survival and lifespan across many species (Broughton and Partridge 2009). 
These findings, in line with previous studies (Arkins et al. 1995; Barrett et al. 
2015; Suh et al. 2013; Wynes and Riches 2003), show that Igf1 expression is 
inhibited by pro-inflammatory stimuli and enhanced in anti-inflammatory 
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environments. Thus, the Igf1 expression decrease caused by Trem2 
deficiency may suggest a microglial phenotype shift towards pro-inflammatory 
activation and away from non-inflammatory, and a decrease of the pro-
survival role of IGF1 on neurons.  In both the human disease and in 
transgenic mouse models of AD, microglia have greatly increased levels of 
Trem2 (Cheng-Hathaway et al. 2018; Jay et al. 2015; Lue et al. 2015; Ma et 
al. 2016; Melchior et al. 2010; Song et al. 2018) and this is strongly correlated 
with plaque load (Matarin et al. 2015). It has been reported that the microglia 
specifically clustering around the plaques and associated with AD have 
considerably higher Igf1 expression than those distant from plaques 
(Kamphuis et al. 2012; Keren-Shaul et al. 2017), and the present data confirm 
that this is likely an effect of the higher Trem2 expression.  
 
4.3. Trem2 knockdown decreases the effects of the anti-inflammatory 
stimulus IL4 by decreasing levels of the transcription factor STAT6 
 
In this study we have further investigated the role of TREM2 and effects on 
Trem2 expression in microglia polarized to anti-inflammatory or pro-
inflammatory phenotypes. Our results suggest that there is cross-talk between 
the TREM2 and anti-inflammatory IL4 signaling pathways, in that TREM2 
knockdown decreases levels of the STAT6 transcription factor, which is 
downstream of IL4 (Ohmori and Hamilton 2000). As the IL4-induced Arg1 up-
regulation is critically dependent on phosphorylation of STAT6 (Gray et al. 
2005), this thus suggests that TREM2 signaling functions in parallel to support 
IL4-induced STAT6-gene transcription by supporting overall levels of STAT6. 
Decreased Trem2 expression in both primary microglia models resulted in a 
decrease in IL4-induced Arg1 expression.  
 
ARG1 is an important anti-inflammatory marker induced upon IL4 stimulation. 
ARG1 in myeloid cells mainly functions as an enzyme to hydrolyze arginine to 
produce ornithine, which both promotes tissue repair through generation of 
polyamines and collagens, and also reduces nitric oxide production from 
inducible nitric oxide synthase through decreasing intracellular arginine 
availability (Mills et al. 2000; Modolell et al. 1995; Yang and Ming 2014). Our 
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findings in cultured primary microglia suggest an attenuated anti-inflammatory 
phenotype with reduced expression of Trem2, with both the RNAi and the 
Trem2 R47H mutation substantially inhibiting this IL4-induced microglial 
response (Figure 11).  
 
It has also been suggested in macrophages that STAT6 is essential for IL4-
mediated up-regulation of Igf1 expression (Wynes and Riches 2003). While 
there is a decrease in Igf1 expression in the cultured microglia in this present 
study, this is independent of IL4, occurring also under control conditions when 
Trem2 is knocked down. Therefore, it is possible that the decrease in Igf1 in 
the Trem2-deficient microglia results from decreased STAT6 levels.  
 
In hippocampal homogenates from young adult Trem2 R47H mice, we did not 
see differences in expression of the genes we studied, including Stat6 and 
Igf1, despite a slight but significant reduction in the number of microglia. Lack 
of gene expression changes in vivo may be due to a supportive environment 
from healthy neurons and astrocytes, providing regulating input to the 
microglia in young mice. Other studies have not revealed obvious phenotypes 
in young Trem2 R47H expressing mice, or even Trem2 knockout mice, unless 
they are bred to amyloid mouse models (Song et al. 2018), and so future 
studies need to characterize these pathways in Trem2 R47H mice crossed 
with amyloid models, or in aged mice. The effects seen in the primary cultured 
microglia probably reflect a different mean activation state from microglia in 
the brain environment. However the pathway interactions described here 
between Trem2 expression and other genes, in primary microglial cultures, 
nevertheless reflects effects that Trem2 can have under particular conditions. 
This also applies to the relationship between Trem2 expression and the IL4-
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4.4. Pro-inflammatory stimuli prevent the effects of TREM2 by inhibiting 
its expression, similar to the effect seen in microglia from Trem2 R47H 
KI mice 
 
With LPS stimulation, primary microglia from WT mice exhibited a robust pro-
inflammatory response in microglia, as measured by strong up-regulation of 
Tnf and Il1b expression (Figure 11). In contrast IL4 stimulation had little effect 
on Trem2 expression. In agreement with previous findings (Owens et al. 
2017), LPS largely suppressed Trem2 expression with a decrease in 
expression beginning as early as 3 hr after LPS application and reaching 
more than an 85% decrease by 24 hr.  This finding is consistent with previous 
studies showing that LPS/IFNγ stimulation down-regulated Trem2 expression 
via TLR4 receptors in cell lines and primary cultures of 
microglia/macrophages and also in mouse brains (Owens et al. 2017; Schmid 
et al. 2002; Turnbull et al. 2006; Zheng et al. 2016). Moreover, Owens and 
colleagues (2017) showed that treatment with pro-inflammatory mediators 
engaging other Toll-like receptors (TLRs) also suppressed Trem2 expression 
in the BV-2 cell line, albeit with slightly different potency. This suggests that 
the Trem2 down-regulation is not specific to LPS-TLR4 signaling but perhaps 
a common event occurring in microglial induced by various classical pro-
inflammatory stimuli. While, under conditions of Trem2 knockdown, the levels 
of expression were even lower after 24 hr exposure to LPS, it is not surprising 
that this additional knockdown had little effect on the expression of LPS-
induced gene expression as so little Trem2 expression remained, even in the 
control microglia. Hence, in conditions of Trem2 knockdown, very similar LPS-
induced up-regulation of Tnf and Il1b expression resulted. It was interesting to 
note however that in the microglia originating from Trem2 R47H KI mice with 
a similar level of Trem2 down-regulation that there was about a 30% increase 
in the activation of Tnf compared to WT mice possibly suggesting that the 
Trem2 R47H mutation further enhances this effect. There are other possible 
explanations for this difference however as the down-regulation of Trem2 in 
these mice is present throughout life and so these microglia may have a 
different state when isolated than those in which Trem2 is knocked down 
acutely. 
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It has been suggested that the SPI1 transcription factor (PU.1) is responsible 
for transcription of Trem2, at least in the BV-2 cell line (Huang et al. 2017; 
Satoh et al. 2014), but in our primary microglia, LPS significantly increased 
the expression of Spi1, whereas Trem2 expression was strongly suppressed 
suggesting that, at least in this context, factors other than SPI1 also regulate 
Trem2 expression. 
 
Taken together, pro-inflammatory mediators, either locally produced or 
infiltrating into the CNS from the periphery, could induce down-regulation of 
microglial Trem2 expression and subsequently induce a microglial state with 
low TREM2-signaling (Figure 11). This might reflect a mechanism for 
microglia to perform specific functional requirements under pro-inflammatory 
conditions. Although, accumulated pro-inflammation and oxidative stress in 
the brain, which is often observed in aged brains and aged microglia 
(Godbout et al. 2005; Lee et al. 2000; Prolla 2002; Sierra et al. 2007; 
Verbitsky et al. 2004), could cause sustained suppression of Trem2 
expression and thus an impairment of TREM2-dependent microglial functions. 
This might be one of the major mechanisms underlying TREM2 dysfunction 
that contributes to sporadic AD progression with advanced age, since TREM2 
variants associated with increased AD risk are extremely rare in frequency in 
humans (Guerreiro et al. 2013b). It is, however, important to note that, in 
conditions of decreased Trem2 expression in the Trem2 R47H KI mice, the 
number of IBA1-positive mouse microglia was decreased in hippocampal 
sections. However, when Trem2 was almost completely inhibited by the pro-
inflammatory stimulus, this does not result in obvious changes in Aif1 
expression, suggesting that under these conditions additional factors control 
Aif1 expression in individual microglia and this could prevent a loss of 
microglia from undermining the pro-inflammatory response. Moreover 
increased Trem2 expression as occurs in Alzheimer’s disease (Cheng-
Hathaway et al. 2018; Jay et al. 2015; Lue et al. 2015; Ma et al. 2016; 
Melchior et al. 2010; Song et al. 2018) could protect the brain from the 
damaging effects of inflammation.  
 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/449884doi: bioRxiv preprint first posted online Oct. 22, 2018; 
	   38	  
4.5. Functions of TREM2 in Alzheimer’s disease and the effect of the 
R47H mutation  
 
Recent important studies have also shown that the R47H variant of Trem2 
acts by loss-of-function and impairs the microglial response to amyloid 
pathology by regulating microglial number around plaques and microglial 
activity, but anti-inflammatory signaling was not studied (Cheng-Hathaway et 
al. 2018; Song et al. 2018). Thus, an important issue about microglial 
activation in vivo has to be carefully considered: in contrast to populations of 
microglia polarized with purified LPS or IL4 stimuli in vitro, microglia in vivo 
probably never receive such simple stimuli to govern their activation status or 
at least not across the whole population. Instead, they are modulated by 
mixed cues including various regulatory signals from the local environment 
(e.g. from neurons and astrocytes), which could possibly lead to a more 
mixed, dynamic and context-dependent microglial phenotype in vivo. There is 
increasing evidence that reactive microglia in diseased brains demonstrate a 
mixed phenotype with expression of both pro- and anti-inflammatory markers, 
even at the single-cell level, rather than completely reproducing the 
phenotype obtained from homogenous in vitro polarization studies (Chiu et al. 
2013; Holtman et al. 2015; Kim et al. 2016; Morganti et al. 2016). Indeed, a 
recent study identified a unique transcriptional signature in phagocytic 
microglia associated with amyloid plaques, which was in part dependent on 
Trem2 and included Igf1 and Csf1 (Keren-Shaul et al. 2017). Therefore, we 
are cautious in directly applying the in vitro phenotype to interpretation of in 
vivo microglial activation. However, we propose pro- and anti-inflammatory 
stimuli still represent an important part of the driving factors determining 
where in the entire multidimensional continuum of microglial activation 
microglia fall and understanding their effects separately and without the 
influence of other cell types may help to differentiate possible methods for 
moderating function in disease.  
 
Thus, to study the relevance of TREM2 in regulating microglial activation, we 
used the polarization experiments to dissect the reaction of microglia in 
response to either pro- or anti-inflammatory stimuli and investigate the effects 
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of Trem2 deficiency in each direction. Overall, our data shows that decreased 
expression of Trem2 has acute and chronic effects on a subset of non-
inflammatory functions in microglial cells that overlap with IL4 anti-
inflammatory signaling (Figure 11). Moreover, Trem2 seems to support the 
survival of microglia at least in part via expression of the Csf1r. Interestingly, 
when we tested expression of genes that show substantial changes in 
transgenic mice associated with AD (Matarin et al. 2015) a number of aspects 
of gene expression were mimicked by anti-inflammatory IL4 stimulation, 
whereas the pro-inflammatory effects of LPS had the opposite effect, leading 
to almost complete down-regulation of Trem2 expression. This suggests that 
the very strong microglial response to plaque deposition that we have 
previously reported in transgenic mice (Matarin et al. 2015), particularly the up 
to 6-fold increase in Trem2 expression, is a protective anti-inflammatory 
response that may contribute to the resistance of mice with a heavy amyloid 
load from developing the full AD pathology of Tau tangles and 
neurodegeneration. The balance of anti-inflammatory and pro-inflammatory 
phenotype is very likely related to the balance between microglia protecting 
against or exacerbating the progression of AD. Generally, Trem2 seems to 
enhance the anti-inflammatory phenotype protecting against disease 
progression and moreover may increase the number of protective microglia. 
Pro-inflammatory stimuli inhibit this effect by down-regulating the expression 
of Trem2. Although in this study, the down-regulation of Trem2 expression in 
the Trem2 R47H KI mice which is not reflected in humans with this mutation, 
means that we can conclude little about the effect of the R47H mutation itself, 
this is nevertheless a model for loss of function of Trem2 and validates our 
findings on the effects of siRNA-induced knockdown. Our findings are thus 
compatible with increased expression of TREM2 in Alzheimer’s disease 
having a protective function slowing disease progression and hence loss of 
function due to the presence of the Trem2 R47H mutation increasing the 
chance of AD reaching the stage of diagnosis. Further work into the molecular 
pathways regulated by TREM2, particularly the cross-talk with anti-
inflammatory pathways, may provide important insights for therapeutic 
approaches.  
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Figure legends 
 
FIGURE 1.  Establishing the in vitro primary microglial model of acute 
Trem2 knockdown.  
(a) Schedule of the in vitro Trem2 knockdown experiment, and treatment with 
LPS or IL4. (b) Left panel: primary microglia stained with an antibody against 
IBA1 and DAPI. Right panel: a higher-magnification image showing the 
morphology of microglia in vitro. (c) Pro- and anti-inflammatory gene 
expression changes in primary microglia with either LPS or IL4 treatment. 
N=3-6 independent experiments. Data shown as mean ± SEM.  
 
FIGURE 2. Trem2 knockdown induced impaired phagocytosis in primary 
microglia. (a) Comparison of Trem2 knockdown in the presence of 3 siRNA 
sequences vs. non-targeting siRNA in BV-2 cell cultures (N=3). The siRNA 
No. 2 was chosen for the following in vitro acute Trem2-knockdown 
experiments due to its high knockdown levels. (b) Trem2 siRNA efficiency 
tested with RT-qPCR at 72 hr after transfection in primary microglia. N=13 
independent cell preparations. (c) Phagocytosis assay was performed 
using pHrodo-conjugated E. coli and analyzed by FACS. As a negative 
control, phagocytosis was inhibited with 10 mM cytochalasin D. Left and 
middle panels: a representative experiment. Left panel: forward (FSC-H) 
versus side (SSC-H) scatter of light to allow identification of single microglial 
cells of the expected size and granularity (shown within the blue gate). Middle 
panel: frequency of microglia containing different levels of phagocytosed 
fluorescent bacteria. Right panel: phagocytosis in microglia with Trem2 
knockdown. N=3 independent experiments. Data shown as mean ± SEM. 
Paired t-test (paired within each culture preparation); * p<0.05, ** p<0.01, *** 
p<0.001, ****p<0.0001.  
  
FIGURE 3. Gene expression changes in primary microglia with acute 
Trem2 knockdown. The mRNA levels of individual genes at 72 hours post 
transfection were first normalized to Rps28, and then the relative fold change 
in the knockdown was calculated versus the negative control from the same 
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batch of cell preparation (shown with a dotted line at 1). N=13 independent 
cell preparations. Data shown as mean ± SEM. One-sample t-test with 
Bonferroni correction; * p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001.  
 
FIGURE 4. LPS suppression of Trem2 expression in primary microglia 
results in little effect of Trem2 knockdown on LPS-induced gene 
expression.  (a) The effect of LPS on Trem2 expression with and without 
Trem2 knockdown. Gene expression levels were normalized to Rps28 and 
calculated as fold change relative to the negative control without LPS 
treatment in each individual culture preparation. (b) Tnf and Il1b expression, 
as examples of pro-inflammatory genes, were greatly up-regulated in primary 
microglia after LPS application. There was no significant difference between 
Trem2 knockdown and negative controls. (c) ELISA analysis of the microglial 
supernatants showed that the secreted TNF-alpha levels in the medium were 
not significantly affected by Trem2 knockdown. (d) Expression levels (RT-
qPCR) of C1qa, Cd68, Csf1r, Igf1, Pik3cg and Spi1 under the LPS-stimulated 
conditions in Trem2-knockdown microglia compared to negative controls. 
N=3-6 (RT-qPCR) and 4 (ELISA) independent microglial preparations. Data 
shown as mean ± SEM. Two-way ANOVA with significant main effect of LPS 
incubation time and Trem2 knockdown indicated as horizontal and vertical 
lines respectively. The only significant interactions between LPS treatment 
and Trem2 knockdown were in Trem2 expression (panel a) and Igf1 
expression (panel d), and so Sidak’s post hoc tests were performed to test 
pairwise significance between the negative siRNA control and Trem2 
knockdown. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
 
FIGURE 5. Trem2 knockdown impairs the IL4-induced anti-inflammatory 
response of primary microglia. (a) Trem2 gene expression was not 
significantly influenced by IL4 stimulation. (b) Arg1 and Tgfb1 expression, as 
markers of the anti-inflammatory response, showed significant up-regulation 
with time after IL4 application. Particularly, Trem2 knockdown greatly 
decreased IL4-induced Arg1 expression compared to negative controls. (c) 
Expression of the pro-inflammatory genes Tnf and Il1b were inhibited with 
time after IL4 application. Trem2 knockdown resulted in significantly 
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decreased Tnf expression, though it did not change the effect of IL4. Gene 
expression levels were normalized to Rps28 and calculated as fold change 
relative to the negative control without IL4 treatment in each individual culture 
preparation. N=7-9 independent experiments. Data shown as mean ± SEM. 
Two-way ANOVA with significant main effect of IL4 incubation time and 
Trem2 knockdown indicated as horizontal and vertical lines respectively. A 
significant interaction between IL4 treatment and Trem2 knockdown was seen 
only in Arg1 expression (panel b), and so Sidak’s post hoc tests were 
performed to test pairwise significance between the negative siRNA control 
and Trem2 knockdown. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
 
FIGURE 6. Effects of Trem2 knockdown on gene expression changes in 
primary microglia with IL4 treatment. Gene expression levels were 
normalized to Rps28 and calculated as fold change relative to the negative 
control without IL4 treatment in each individual culture preparation. N=7-9 
independent experiments. Data shown as mean ± SEM. Two-way ANOVA; 
significant main effects of IL4 treatment time and Trem2-knockdown indicated 
by horizontal and vertical lines respectively, no significant interactions were 
seen between IL4 treatment and Trem2 knockdown. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
 
FIGURE 7. Trem2 knockdown resulted in significantly decreased total 
STAT6 levels and AKT phosphorylation in primary microglia in vitro. (a-
b) Total and phosphorylated STAT6 protein levels in primary microglia treated 
with IL4 and Trem2 siRNA were analyzed with western blot. N=4 independent 
experiments. (c) Stat6 gene expression levels in primary microglia, assessed 
by RT-qPCR (n=3 independent experiments). (d-e) Total and phosphorylated 
(at Thr308 and Ser473) AKT protein levels analyzed by western blot. N=4 
independent experiments. Protein levels were normalized to beta-actin and 
gene expression was normalized to Rps28. Fold change was calculated 
relative to the negative control without IL4 treatment in each individual culture 
preparation. Note that phosphorylated STAT6 was not detectable under 
control conditions and so under IL4 conditions the effect of Trem2 knockdown 
was calculated as fold change relative to control cells. Data shown as mean ± 
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SEM. With the exception of phosphorylated STAT6, data were analyzed by 
two-way ANOVA; significant main effects of IL4 treatment and Trem2-
knockdown indicated by horizontal and vertical lines respectively, no 
significant interactions were seen between IL4 treatment and Trem2 
knockdown. Phosphorylated STAT6 was analyzed by a one-sample t-test. * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
 
FIGURE 8. Trem2 R47H knock-in mice (4 months old) showed significant 
down-regulation of Trem2 expression, and decreased microglia density 
and CD68 levels in the hippocampus. (a) Gene expression in hippocampal 
homogenates from homozygous (HO) and heterozygous (HE) Trem2 R47H KI 
mice relative to Rps28 and then expressed relative to WT within the batch. 
N=6-7 mice per group. Data shown as mean ± SEM. One-way ANOVA 
showed a significant main effect of genotype for Trem2 expression only, and 
so Sidak’s post hoc tests were used to test pairwise significance between the 
three genotypes. * p<0.05, ** p<0.01, *** p<0.001. (b) Representative images 
showing AIF1 and CD68 immuno-staining of microglia with DAPI in the 
hippocampal CA1 regions from WT and HO-Trem2 R47H KI mice. The layers 
from left are SO (stratum oriens), SP (stratum pyramidale), SR (stratum 
radiatum), and SLM (stratum lacunosum-moleculare). Scale bar: 100 µm. (c) 
Left panel: total microglia density in all four CA1 layers was decreased in HO-
Trem2 R47H KI mice. Middle panel: density of CD68 positive microglia 
decreased in HO-Trem2 R47H KI mice. Right panel: proportion of CD68 
positive microglia was significantly lower in HO-Trem2 R47H KI mice. N=5-6 
mice per group. Data shown as mean ± SEM. Two-way ANOVA with 
significant main effect of Trem2 genotype indicated with vertical lines, no 
significant interactions were seen between hippocampal layer and Trem2 
genotype. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
FIGURE 9. Primary microglia from Trem2 R47H knock-in mice show 
decreased Trem2 expression, and changes to canonical markers in 
response to IL4 and LPS. (a) Expression of Trem2. (b) Expression of pro-
inflammatory markers, Tnf and Il1b. (c) Expression of anti-inflammatory 
markers, Tgf1b and Arg1. Gene expression was normalized to Rps28.  Dotted 
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boxes show fold changes relative to untreated microglia. N=14-15 mice per 
genotype, except for genes Il1b and Tgfb1, where N=8-10 mice. Data shown 
as mean ± SEM.  Two-way ANOVA with Bonferroni correction (for all genes 
except Arg1) were undertaken separately for IL4 and LPS using the same 
control data. Significant main effect of treatment (IL4 or LPS) and genotype 
indicated as horizontal and vertical lines respectively. A significant interaction 
between treatment and genotype was seen for only Trem2 and Tnf 
expression, and so Sidak’s post hoc tests were performed to test pairwise 
significance between the three genotypes within a treatment group, marked 
above individual groups for Tnf. For Trem2 the interaction reflects a lack of 
effect of genotype in the LPS treated microglia. Arg1 was analyzed by one-
way ANOVA (p = 0.002) followed by Sidak’s multiple comparisons to test 
pairwise significance between the three genotypes. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
 
FIGURE 10. Altered gene expression profile in primary microglia from 
Trem2 R47H knock-in mice. Expression of Aif1, Csf1r, Plcg2, Igf1, Cd68 and 
C1qa. Gene expression was normalized to Rps28.  N=14-15 mice per 
genotype (except for genes Igf1, Cd68 and C1qa where N=8-10 mice). Data 
shown as mean ± SEM. Two-way ANOVA with Bonferroni correction  (for all 
genes except Arg1) were undertaken separately for IL4 and LPS using the 
same control data. Significant main effect of treatment (IL4 or LPS) and 
genotype indicated as horizontal and vertical lines respectively. A significant 
interaction between treatment and genotype was seen for only Igf1 and C1qa 
expression, and so Sidak’s post hoc tests were performed to test pairwise 
significance between the three genotypes within a treatment group reflecting a 
lack of effect of genotype in the LPS treated microglia. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. 
  
FIGURE 11. Proposed model of the involvement of TREM2 in IL4-
induced anti-inflammatory response. LPS induces pro-inflammatory 
activation of microglia, which is accompanied by down-regulated Trem2 
expression, and so microglia with reduced TREM2 activity can undergo 
normal, or even enhanced, pro-inflammatory activation. Under non-stimulated 
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conditions, a number of microglial genes are down-regulated when TREM2 
activity is decreased, such as Csf1r expression, which may reduce the 
survival of microglia. However, IL4 induces an anti-inflammatory phenotype of 
microglia. As our data suggest, TREM2 signaling is involved in maintenance 
of microglial STAT6 levels, which in the IL4 pathway is phosphorylated and 
translocates to the nucleus and functions as a key transcription factor for IL4-
induced gene expression changes, such as for Arg1. Thus, Trem2 deficiency 
results in decreased STAT6 levels in the microglial, which leads to an 
impairment of IL4-induced signaling. TREM2 also regulates the levels of a 
number of genes that are up-regulated by IL4 (and suppressed by LPS), such 
as Igf1 and C1qa. 
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